ArticleInternational journal of molecular sciences2025
Investigation of Anti-Cancer Properties of Nano-Encapsulated Ciprofloxacin Using 3D Cancer Cell Spheroids as Tumour Models.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ciprofloxacin beyond antibacterial therapy: pharmacological mechanisms, anticancer activity, and translational limitations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Marbofloxacin Suppresses Breast Cancer Growth Through Oxidative Stress and Metabolic Reprogramming with Predicted HSP90AA1-EGFR Network Modulation.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Anticancer Activity of Ethanolic Extract ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bladder cancer remains a significant global health challenge, necessitating innovative therapeutic strategies to enhance treatment efficacy. This study investigates the potential of chitosan nanoparticles as a drug delivery system, using ciprofloxacin as a model compound and utilizing a 3D spheroid model of bladder cancer that better reflects in vivo tumour conditions. The encapsulation efficiency of ciprofloxacin was optimized on the appropriate mass ratio of chitosan to cross-linking tripolyphosphate (TPP) polyanion. The resulting spherical chitosan nanocapsules loaded with ciprofloxacin demonstrated improved stability and controlled drug release, addressing the limitations of non-encapsulated ciprofloxacin. In 3D T24 bladder cancer spheroids, encapsulated ciprofloxacin exhibited enhanced cytotoxicity compared to free-drug formulations, with significant effects observed at ciprofloxacin concentrations of 500 and 1000 μM after 48 and 72 h of exposure. The 3D spheroid model, which better mimics the tumour microenvironment than 2D cultures, enabled a more accurate drug efficacy evaluation. The results demonstrate that chitosan nanocapsules can improve the delivery and cytotoxic profile of ciprofloxacin in vitro, indicating their potential for further development as carriers in localized bladder cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.